Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study

• Published in: Journal of clinical oncology Vol. 8; no. 5; p. 892
• Main Authors: McCracken, J D, Janaki, L M, Crowley, J J, Taylor, S A, Giri, P G, Weiss, G B, Gordon, Jr, W, Baker, L H, Mansouri, A, Kuebler, J P
• Format: Journal Article
• Language: English
• Published: United States 01-05-1990
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Small Cell - drug therapy; Carcinoma, Small Cell - mortality; Carcinoma, Small Cell - radiotherapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Combined Modality Therapy; Drug Evaluation; Etoposide - administration & dosage; Etoposide - adverse effects; Female; Humans; Leukopenia - chemically induced; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - radiotherapy; Male; Middle Aged; Multicenter Studies as Topic; Remission Induction; Survival Rate; United States; Vincristine - administration & dosage; Vincristine - adverse effects; United States
• ISSN: 0732-183X
• DOI: 10.1200/JCO.1990.8.5.892

The Southwest Oncology Group (SWOG) has conducted a phase II study to explore the efficacy and toxicity of initial, concurrent use of radiation therapy with cisplatin, etoposide (VP-16), and vincristine in limited-stage small-cell carcinoma of the lung. Two courses of cisplatin, VP-16, and vincristine chemotherapy were given with concurrent radiotherapy (XRT) to the primary tumor to a total dose of 4,500 cGy. Elective brain XRT was given to all patients concurrent with a third course of cisplatin/VP-16 therapy. Consolidation chemotherapy consisting of vincristine, methotrexate, and VP-16 alternating with Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) and cyclophosphamide, was given for 12 weeks following the initial induction chemotherapy/XRT program. Patients with a complete response had all therapy discontinued. Among 154 eligible patients treated, the complete response rate was 56%, with a partial response rate of 27%. The median survival is 17.5 months with an estimated 30% survival rate at 4 years from initiation of treatment. Combined modality toxicities were acceptable with the predominant toxicity being moderate to severe leukopenia and mild radiation esophagitis. The results of this treatment program appear superior to any previously reported by our group and compare favorably to those in the literature at large.